• Executed exclusive R&D agreement with Superpower, expediting path to revenue
• Tutelix fast tracks pivotal trial program following Series A capital raise
• TetraDerm scar prevention reaches major clinical milestone

Tetratherix Limited (ASX: TTX) has reported a strong Q3 FY26, with key highlights including an exclusive R&D agreement with Superpower, progress on Tutelix's pivotal trial, and major clinical milestones for TetraDerm in scar prevention. The company executed an exclusive R&D agreement with Superpower Health Inc, which will pay Tetratherix US$3 million per year for up to 10 years and purchase the Tetramatrix™ platform polymer, branded STEPP, for drug delivery applications. Tutelix has progressed its prostate spacing clinical trial with promising results, and is rapidly moving into an international pivotal study. Tetratherix also reported positive interim results from the TetraDerm clinical trial, with negligible scar formation observed in patients. The company continues to progress its bone regeneration products Tegenix and TegenEOS towards FDA 510(k) clearance, and construction of its expanded advanced manufacturing facility in Alexandria, NSW is ongoing. Tetratherix ended the quarter with a strong cash position of $19.2 million and no debt.

Tetratherix expects to receive FDA 510(k) clearance for its Tegenix and TegenEOS bone regeneration products in CY26.

Tetratherix is focused on prioritizing the highest return partnerships for its TegenEOS product, as well as progressing the regulatory clearance path and commercialization activities for its bone regeneration franchise. The company is also advancing its TetraDerm scar prevention program, with Cohort 3 of the clinical trial now underway.